No new side effects found in COVID-19 antiviral Favipiravir: Glenmark

no new side effects found in covid 19 antiviral favipiravir glenmark

Sumary of No new side effects found in COVID-19 antiviral Favipiravir: Glenmark:

  • Drug maker Glenmark , on September 15, announced that it had found no new side effects in the post marketing surveillance (PMS) study on Favipiravir (FabiFlu) in over 1,000 COVID-19 patients.
  • The PMS study commenced in July 2020 to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients.
  • A total of 1083 patients were enrolled in the prospective, open label, multicentre, single arm study.
  • Glenmark’s PMS study is the first and largest post marketing study conducted in India on Favipiravir in mild to moderate COVID-19 patients.
  • The study was conducted in patients in line with the approved indication of the drug.
  • “This study was crucial as it examined the safety and efficacy of FabiFlu in real-world settings, where multiple variables can impact the results,”said Alok Malik, Group Vice President &

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close